JP2019519492A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519492A5 JP2019519492A5 JP2018558733A JP2018558733A JP2019519492A5 JP 2019519492 A5 JP2019519492 A5 JP 2019519492A5 JP 2018558733 A JP2018558733 A JP 2018558733A JP 2018558733 A JP2018558733 A JP 2018558733A JP 2019519492 A5 JP2019519492 A5 JP 2019519492A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333643P | 2016-05-09 | 2016-05-09 | |
| US62/333,643 | 2016-05-09 | ||
| PCT/US2017/031791 WO2017196867A1 (en) | 2016-05-09 | 2017-05-09 | Anti-pd-l1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519492A JP2019519492A (ja) | 2019-07-11 |
| JP2019519492A5 true JP2019519492A5 (enExample) | 2020-06-18 |
| JP6979971B2 JP6979971B2 (ja) | 2021-12-15 |
Family
ID=58710168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558733A Expired - Fee Related JP6979971B2 (ja) | 2016-05-09 | 2017-05-09 | 抗ｐｄ−ｌ１抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10954302B2 (enExample) |
| EP (1) | EP3455257B1 (enExample) |
| JP (1) | JP6979971B2 (enExample) |
| KR (1) | KR102343742B1 (enExample) |
| CN (1) | CN109311985B (enExample) |
| AU (1) | AU2017264683B2 (enExample) |
| CA (1) | CA3021669A1 (enExample) |
| DK (1) | DK3455257T3 (enExample) |
| ES (1) | ES2899361T3 (enExample) |
| HU (1) | HUE055972T2 (enExample) |
| IL (1) | IL262295B2 (enExample) |
| PL (1) | PL3455257T3 (enExample) |
| PT (1) | PT3455257T (enExample) |
| SG (1) | SG11201809336QA (enExample) |
| WO (1) | WO2017196867A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| CN105722855B (zh) | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP4011910A1 (en) | 2014-04-03 | 2022-06-15 | IGM Biosciences, Inc. | Modified j-chain |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| KR102357312B1 (ko) | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2016249404B2 (en) | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| WO2017196867A1 (en) * | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CA3055790A1 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences, Inc. | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| US11673954B2 (en) | 2017-11-17 | 2023-06-13 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-L1 |
| WO2019109974A1 (zh) * | 2017-12-06 | 2019-06-13 | 正大天晴药业集团南京顺欣制药有限公司 | 抗pd-l1抗体及其抗原结合片段 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| MX2020007406A (es) * | 2018-01-10 | 2020-09-14 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. |
| EP3740509A4 (en) * | 2018-01-17 | 2022-06-22 | Apexigen, Inc. | Anti-pd-l1 antibodies and methods of use |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| TWI756621B (zh) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥（蘇州）有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
| MX2021010116A (es) * | 2019-02-21 | 2021-09-23 | Eucure Beijing Biopharma Co Ltd | Anticuerpo anti-pd-l1 y uso de este. |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| JP2022544405A (ja) * | 2019-08-15 | 2022-10-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 免疫刺激性多量体型結合分子 |
| CN110746493A (zh) * | 2019-09-06 | 2020-02-04 | 中国药科大学 | 一种pd-l1拮抗剂多肽及其应用 |
| CN113121686B (zh) * | 2019-12-31 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 抗pd-l1抗体及其应用 |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| JP2023522962A (ja) | 2020-04-22 | 2023-06-01 | アイジーエム バイオサイエンシズ インコーポレイテッド | Ｐｄ－１アゴニスト多量体結合分子 |
| CN113754775A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pd-l1和her2的双特异性抗体 |
| WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| US20230058162A1 (en) * | 2020-07-27 | 2023-02-23 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| KR20250140647A (ko) * | 2020-08-03 | 2025-09-25 | 난트셀, 인크. | Il-15 초작용제에 대한 약물-특이적 약동학 검정 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN113943371B (zh) * | 2021-11-01 | 2023-05-05 | 达石药业(广东)有限公司 | 一种抗her2/抗pd-l1双功能抗体及其应用 |
| WO2023178253A2 (en) * | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
| JP2025523387A (ja) | 2022-06-07 | 2025-07-23 | ジェネンテック， インコーポレイテッド | 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法 |
| JP2026517051A (ja) * | 2023-01-18 | 2026-05-28 | エルピサイエンス・（スージョウ）・バイオファーマ，リミテッド | 抗ｐｄｌ１単一ドメイン抗体、融合タンパク質及びその使用 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| AU2005304973A1 (en) | 2004-11-05 | 2006-05-18 | Palingen, Inc. | Antibody induced cell membrane wounding |
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| BR112014012819B1 (pt) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
| CN105722855B (zh) | 2013-09-05 | 2021-04-23 | Igm生物科学股份有限公司 | 恒定链经修饰的双特异性五价和六价Ig-M抗体 |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015120474A1 (en) | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| EP4011910A1 (en) * | 2014-04-03 | 2022-06-15 | IGM Biosciences, Inc. | Modified j-chain |
| US9885721B2 (en) * | 2014-05-29 | 2018-02-06 | Spring Bioscience Corporation | PD-L1 antibodies and uses thereof |
| TWI726608B (zh) * | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| SG10201901057UA (en) * | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| KR102357312B1 (ko) | 2015-03-04 | 2022-02-03 | 아이쥐엠 바이오사이언스 인코포레이티드 | Ｃｄ20 결합 분자 및 그의 용도 |
| WO2016154593A1 (en) | 2015-03-25 | 2016-09-29 | Igm Biosciences, Inc. | Multi-valent hepatitis b virus antigen binding molecules and uses thereof |
| AU2016249404B2 (en) | 2015-04-17 | 2021-01-21 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| ES2819870T3 (es) * | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| WO2017196867A1 (en) * | 2016-05-09 | 2017-11-16 | Igm Biosciences, Inc. | Anti-pd-l1 antibodies |
| CA3030659A1 (en) | 2016-07-20 | 2018-01-25 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| AU2017299608A1 (en) | 2016-07-20 | 2019-02-07 | Igm Biosciences, Inc. | Multimeric CD137/4-1BB binding molecules and uses thereof |
| US20190330374A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| US20190338041A1 (en) | 2016-07-20 | 2019-11-07 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| CA3055790A1 (en) | 2017-04-07 | 2018-10-11 | Igm Biosciences, Inc. | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function |
| EP3759229A4 (en) | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| CN111787951B (zh) | 2018-03-01 | 2025-06-17 | Igm生物科学股份有限公司 | 影响IgM血清半衰期的IgM Fc和J链突变 |
| AU2019368289A1 (en) | 2018-10-23 | 2021-04-29 | Igm Biosciences, Inc. | Multivalent IgM- and IgA-Fc-based binding molecules |
| US20220106398A1 (en) | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
-
2017
- 2017-05-09 WO PCT/US2017/031791 patent/WO2017196867A1/en not_active Ceased
- 2017-05-09 EP EP17724263.3A patent/EP3455257B1/en active Active
- 2017-05-09 PT PT177242633T patent/PT3455257T/pt unknown
- 2017-05-09 CN CN201780027997.1A patent/CN109311985B/zh not_active Expired - Fee Related
- 2017-05-09 ES ES17724263T patent/ES2899361T3/es active Active
- 2017-05-09 JP JP2018558733A patent/JP6979971B2/ja not_active Expired - Fee Related
- 2017-05-09 IL IL262295A patent/IL262295B2/en unknown
- 2017-05-09 SG SG11201809336QA patent/SG11201809336QA/en unknown
- 2017-05-09 PL PL17724263T patent/PL3455257T3/pl unknown
- 2017-05-09 DK DK17724263.3T patent/DK3455257T3/da active
- 2017-05-09 KR KR1020187035104A patent/KR102343742B1/ko active Active
- 2017-05-09 AU AU2017264683A patent/AU2017264683B2/en not_active Ceased
- 2017-05-09 HU HUE17724263A patent/HUE055972T2/hu unknown
- 2017-05-09 US US16/098,479 patent/US10954302B2/en active Active
- 2017-05-09 CA CA3021669A patent/CA3021669A1/en active Pending
-
2021
- 2021-02-10 US US17/172,790 patent/US20210163600A1/en not_active Abandoned
-
2023
- 2023-09-07 US US18/463,194 patent/US20240002514A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12528879B2 (en) | Multi-specific binding proteins for cancer treatment | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| JP7809680B2 (ja) | 癌処置のための多重特異性結合タンパク質 | |
| US10604576B2 (en) | Antibodies and immunocytokines | |
| CN114716552B (zh) | 人源化、小鼠或嵌合抗cd47单克隆抗体 | |
| EP3988568A1 (en) | Combination treatment | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| US20220227870A1 (en) | Triple-chain antibody, method for preparation and use thereof | |
| WO2017059387A1 (en) | Binding molecules with modified j-chain | |
| CA3015938A1 (en) | Anti-lag-3 antibodies | |
| JP2019524693A5 (enExample) | ||
| US20240301085A1 (en) | Humanized gpc3 antibody and application thereof | |
| TWI797609B (zh) | 抗pd-1和pd-l1的四價雙特異性抗體 | |
| KR20240049318A (ko) | Fap/cd40 결합 분자 및 이의 의학적 용도 | |
| JP2021512604A5 (enExample) | ||
| CN114829405B (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| CN113811545B (zh) | 对btn2具有特异性的抗体及其用途 | |
| CN119053622A (zh) | 一种抗ceacam5和ceacam6抗体及其应用 | |
| JP2024522172A (ja) | ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック | |
| RU2802272C2 (ru) | Антитело к cd3 и его фармацевтическое применение | |
| HK40128404A (en) | Trop2 antibodies | |
| EA047971B1 (ru) | Dll3/cd3 связывающие белки для лечения рака |